Probably no clinically significant CYP-interactions.

(To be edited, initial data ST OCT 04) The preparation is used in antismoking cure as slow release adhesive (5-16mg/16h), chewing-gum (2-4 mg), nasal spray (0,5 mg/dose), inhalator (10 mg), sublingual resoriblette (2 mg) or lozenge (1 mg). Metabolized in liver, lung and kidneys. More than 20 metabolites are identified,the main metabolite being kotinine. Possibly a CYP1A2-inhibitor. Inducer of CYPs 1A1 and 2E1. (Smoking, but not nicotine, is associated with induction of CYP 1A2).

Uneventful use reported in 2 patients with acute porphyria.